HFS
ALNY icon

Hantz Financial Services’s Alnylam Pharmaceuticals ALNY Stock Holding History

Hantz Financial Services’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.78M Sell
15,883
-1,790
-10% -$540K 0.06% 197
2026
Q1 		$5.85M Buy
17,673
+6,350
+56% +$2.16M 0.09% 157
2025
Q4 		$4.5M Sell
11,323
-1,823
-14% -$807K 0.07% 208
2025
Q3 		$6M Buy
13,146
+12,767
+3,369% +$5.2M 0.09% 188
2025
Q2 		$124K Buy
+379
New +$105K ﹤0.01% 712

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hantz Financial Services's ALNY Position: Q2 2026 in Review

Hantz Financial Services reduced its Alnylam Pharmaceuticals (ALNY) stake by 10% in Q2 2026, selling an estimated $540K and leaving 15,883 shares worth $4.78M. The position accounts for 0.06% of the portfolio, ranked #197.

Hantz Financial Services first reported a position in ALNY in Q2 2025 and has held it in 5 quarters since. The position peaked at $6M in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Hantz Financial Services held 15,883 shares of Alnylam Pharmaceuticals worth $4.78M as of Q2 2026.
  • Hantz Financial Services sold 1,790 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $540K.
  • Alnylam Pharmaceuticals made up 0.06% of Hantz Financial Services's portfolio in Q2 2026, its #197 holding.
  • Hantz Financial Services first reported a position in Alnylam Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Hantz Financial Services's Alnylam Pharmaceuticals position peaked at $6M in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.